CHARIOT trial (cohort A2): A phase I dose-escalation study combining the ATR inhibitor berzosertib with cisplatin and capecitabine
Authors
El Badri, S.Lord, S.
Harman, R.
McIntosh, D.
Mukherjee, S.
Ooms, A.
Parkes, M.
Radhakrishna, Ganesh
Shaw, P. H.
Hawkins, M. A.
Affiliation
Oncology, University of Oxford, OX3 7DQIssue Date
2022
Metadata
Show full item recordCitation
El Badri S, Lord S, Harman R, McIntosh D, Mukherjee S, Ooms A, et al. CHARIOT trial (cohort A2): A phase I dose-escalation study combining the ATR inhibitor berzosertib with cisplatin and capecitabine. Annals of Oncology. 2022 Sep;33(7):S761-S. PubMed PMID: WOS:000866211600477.Journal
Annals of OncologyDOI
10.1016/annonc/annonc1049Additional Links
https://dx.doi.org/10.1016/annonc/annonc1049Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/annonc/annonc1049